Wang Lei

Lei focuses on healthcare and life sciences investments，she led and participated in the investment of Singleron Biotechnologies, COYOTE, Pyrotech, Naxions, Leomed, and Novita.

Prior to joining FreeS, Lei worked in IMS Healthcare, the largest healthcare consulting and market research group in US, providing management consulting service to companies to help them grow in China. Before that, Lei worked in US for about 10 years in Sepracor and Genzyme responsible for brand strategy, brand planning, market analytics and forecasting. Lei is the key launch team member of a recent blockbuster drug LATUDA.

Lei obtained her PhD from the University of Notre Dame and MBA from Boston university focusing on healthcare management.